MS, mass spectrometry; MS/MS, tandem mass spectrometry; m/z, mass-to-charge ratio; DPBS, Dulbecco's phosphate buffered saline; IV, intravenous; PD, pharmacodynamics; PK, pharmacokinetics; RBC, red blood cells (also called erythrocytes); THF, tetrahydrofuran.
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INTRODUCTION
Phosphorylation of xenobiotics is rare, probably due to a strong evolutionary pressure against it (Parkinson et al., 2013) . This has been rationalized for a number of reasons (Parkinson, 2001; Parkinson et al., 2013; Mitchell, 2016) , such as limiting consumption of ATP in cells by xenobiotics, avoiding interference with intracellular signaling, and the assumption that the phosphorylated metabolites are unlikely to be excreted through the cell membrane if formed in hepatocytes or other cells. The topic of xenobiotic phosphorylation has attracted more attention recently, due to intentionally designed kinasesubstrate analogs depending on kinase-catalyzed activation to form phosphorylated active drugs.
Examples include a number of antiviral and anticancer drugs that are nucleoside mimetics requiring phosphorylation to activate, as well as the immunomodulatory drug fingolimod (Mitchell, 2016; Kalász et al., 2013) . Fingolimod is a structural analog of sphingosine and is phosphorylated by sphingosine kinases to become an agonist of the sphingosine-1-phosphate receptor (David et al., 2012; Zollinger et al., 2011; Billich et al., 2003; Mandala et al., 2002) . However, the phosphorylation of fingolimod may still be viewed as an endogenous pathway for the closely-related structural analog of a kinase substrate, rather than as a biotransformation typical for xenobiotics (Zollinger et al. 2011) . Recently, Scheible et al. (2017) have reported a novel conjugation metabolite with phosphoethanolamine as a major metabolite of the MEK1/2 inhibitor pimasertib in plasma and feces of cancer patients. They have suggested that the novel conjugation with phosphoethanolamine may be owing to the structural similarity of the propanediol moiety of pimasertib to glycerol, thus leading to lipid metabolism (Scheible et al., 2017) . Previously, Zollinger et al. (2008) have described that a phosphocholine conjugate of the immunosuppressant everolimus was the most prominent drug metabolite in human and preclinical animal blood. The phosphocholine conjugation following the hydroxylation of a bicyclo[1.1.1]pentane of hepatitis C NS5B inhibitors has also been observed in rat bile by Zhuo et al. (2106) . Both cases of phosphocholine conjugation involve phospholipid synthesis metabolism to xenobiotics that do not appear to have close structural similarity to the endogenous substrates (Zollinger et al, 2008; Zhuo et al. 2016 ).
This article has not been copyedited and formatted. The final version may differ from this version. A pyrimidinone nicotinamide mimetic compound (S)-2-(4-(6-(3,4-dimethylpiperazin-1-yl)-4-methylpyridin-3-yl)phenyl)-8-(hydroxymethyl)quinazolin-4(3H)-one (AZ2381) was identified as an oral lead compound to selectively inhibit the poly-ADP-ribose polymerase catalytic domain of Tankyrases and thus potentially to inhibit the Wnt pathway (Johannes et al., 2015) . In other words, AZ2381 was not designed to be a kinase substrate. When the intended administration route was altered from oral to intravenous (IV) during the drug discovery (Johannes et al., 2015) , a phosphate prodrug of AZ2381 at the benzyl alcohol (Scheme 1) was made to test IV administration as the poor solubility of AZ2381 meant that it is not suitable for IV. During the studies comparing the IV dosed prodrug with orally dosed AZ2381 in mouse, phosphorylated-AZ2381 was unexpectedly detected in mouse plasma samples collected from the AZ2381 dose groups. This present study has confirmed that indeed a rare xenobiotic phosphorylation metabolite was formed in mouse. Perhaps even more surprisingly, the phosphorylation is found to be mediated by red blood cells and the source of the phosphoryl group appears to be inorganic phosphate.
This article has not been copyedited and formatted. The final version may differ from this version. 
MATERIALS AND METHODS
AZ2381 was synthesized as described by Johannes et al. (2015, compound 15 in the Supporting Information of the reference). Chemical synthesis of Phorphorylated-AZ2381 is described here (see Scheme 2 for the two-step synthetic route).
(S)-Di-tert-butyl(2-(4-(6-(3,4-dimethylpiperazin-1-yl)-4-methylpyridin-3-yl)phenyl)-4-oxo-3,4-dihydroquinazolin-8-yl)methyl phosphate (di-tert-butyl-phosphorylated-AZD2381). 1H-Tetrazole (0.45 M in acetonitrile, 8 ml) and di-tert-butyl diethylphosphoramidite (591 mg in 5 ml tetrahydrofuran (THF)) were added to a solution of AZ2381 (180 mg) in 10 ml of THF. The resulting mixture was stirred at room temperature for 50 h. Liquid chromatography-mass spectrometry (LC-MS) indicated the completion of reaction. The reaction mixture was cooled to -78°C, m-chloroperoxybenzoic acid (m-CPBA, 100 mg, 77% in THF, 5 ml) was added to the mixture dropwise. The mixture was stirred at -78°C for 10 min and then the cooling bath was removed. The reaction mixture was checked by LC-UV-MS, which indicated the formation of product and about 22% of intermediate. The mixture was cooled back to -78°C, 40 mg of m-CPBA in 1 ml of THF was added to the mixture. After stirring for 5 min, LC-MS indicated completion of the oxidation. To the resulting mixture was added a solution of saturated NaHCO 3 , followed by dilution with ethyl acetate. The layers were separated, the organic layer was dried with anhydrous Na 2 SO 4 , concentrated, and the residue was purified via normal phase chromatography on silica gel (eluted with 100% dichloromethane to 20% methanol in dichloromethane) to yield the desired Franklin Lakes, NJ). The heparinized mouse plasma was separated from the heparinized whole blood by centrifugation. Rat blood (Nude) was also freshly collected at our laboratory into the same heparin coated tube.
Total leukocytes in the mouse blood were collected by lysing red blood cells (RBC, also called erythrocytes) using the following procedures at room temperature unless specified: Pipetted 1 mL heparin-treated whole blood into a tube containing 10-20 mL of ACK lysing buffer. Allowed the mixture to incubate for 3 -5 minutes. Collected the leukocytes by centrifugation at 300 x g for 5 minutes. were included in the 25 and 90 mg/kg dose groups respectively. However, to minimize the volume of blood withdrawn from individual mice in the PD study, only 2 and 3 animals of the respective 25 and 90 mg/kg group were sampled for blood at each time point. After centrifugation of blood samples at 14500 × g at 4 °C for 5 min, separated plasma samples of 5 µl were transferred to storage tubes, followed by the addition of 20 µl of commercially available blank CD-1 mouse plasma, and then frozen at -20 °C before bioanalysis.
In vitro incubations of AZ2381 in mouse blood and plasma. AZ2381 of 10 µM was incubated in mouse whole blood with heparin as the anticoagulant, in the mouse blood fortified with 5 mM ATP and 10 mM MgCl 2 , in the mouse blood in the presence of 100 mM EDTA, and in the heparinized mouse plasma fortified with 5 mM ATP and 10 mM MgCl 2 , respectively, in capped vials at 37 °C in a shaking water bath. Individual incubation volumes were 250 µL. The incubations were stopped at 2 h by adding equal volumes of acetonitrile. Clear supernatant after centrifugation was transferred to a 96-well plate and diluted with an equal volume of water. Aliquots of 10 µL were injected for LC-UV-MS analysis.
Additionally, a negative control experiment was conducted in DPBS with 5 mM ATP and 10 mM MgCl 2 added. In all in vitro incubations described in this article, AZ2318 was spiked from a 10 mM stock solution in DMSO (i.e. only 0.1% DMSO was introduced to the incubations), ATP and MgCl 2 stock solutions were prepared freshly in DPBS, and EDTA was added from a pH 7.4 buffer solution. When applicable, blank DPBS was added to make up the total volume so that the same slight dilution of blood sample would be applied for all incubation conditions in one in vitro experiment.
In vitro incubations of AZ2381 in mouse leukocytes and RBCs. AZ2381 of 10 µM was incubated in mouse whole blood, and in the total cellular fraction after removal of plasma, in leukocytes and in RBCs, respectively. The mouse blood and whole cellular fractions were fortified with 5 mM ATP and 10 mM Mg 2+ for the incubation. The leukocyte and RBC incubations were carried out with or without adding 
RESULTS
Several metabolites of AZ2381 were observed in the pooled mouse plasma sample collected at 1 h after an oral dose of 90 mg/kg to CD-1 mice in a toxicology study (Fig. 1) , including common oxidation metabolites undergoing N-demethylation (M1), a further N-hydroxylation following the N-demethylation (M2), N-oxidation (M3), and glucuronidation of the parent drug, M1 and M3 (m/z 632, 618, and 648, respectively, Fig. 1 ). In addition, an unexpected phosphorylation metabolite was detected in the mouse plasma (phosphorylated-AZ2381, Fig. 1 ). This phosphorylated metabolite was proven to be identical to the chemically synthesized standard by LC-UV-MS and MS/MS (Supplemental Fig. 1 : the same retention time, the same accurate mass of [M+H] + , and the same MS/MS fragmentation pattern). In addition, a similar plasma metabolite profile of AZ2381 including the same rare phosphorylated metabolite was observed in SCID mouse, with a pooled plasma sample collected at 1 h after a 90 mg/kg oral dose in a PK study (data not shown). The area under the curve of phosphorylated metabolite was determined to be approximately 5% to 10%
that of the parent drug in respective dose groups. Additionally, the dosing formulation check performed during the bioanalysis indicated no trace of contamination by the phosphate prodrug investigated in the same PD study (Supplemental Fig. 2 ).
The phosphorylated metabolite was generated by the incubation of AZ2381 in mouse whole blood with heparin as the anticoagulant (Fig. 3A) . Addition of 5 mM ATP and 10 mM Mg 2+ to the whole blood did not cause a noticeable change in the yield of phosphorylated metabolite (Fig. 3B) . However, the presence of divalent metal ion chelator EDTA diminished the phosphorylation by 84% (Fig. 3C vs. 3A) .
This article has not been copyedited and formatted. The final version may differ from this version. Mouse plasma did not produce any phosphorylated metabolite, in contrast to the whole blood under the same incubation conditions (Fig. 3D vs. 3B ). The phosphorylated metabolite was not detected after a control incubation in a DPBS solution supplemented with ATP and Mg 2+ . In addition, the phosphorylated metabolite was not produced in mouse hepatocytes, when oxidation metabolites (e.g., M1, M2 and M3) and glucuronidation metabolites occurred after the incubation of 10 µM AZ2381 in 2×10 6 cells/mL CD-1 mouse cryopreserved hepatocytes at 37 °C for 2 h (data not shown). The extracted ion chromatograms in for leukocytes in Fig. 4 , also not detected in LC-MS accurate-mass extracted ion chromatograms that are not shown). According to similar phosphorylation yields in three RBC incubations shown in Fig. 5 , additional ATP or Mg 2+ introduced to the RBC incubation did not affect the phosphorylation yield, however, the presence of EDTA diminished the phosphorylation (Fig. 4) . This is similar to that observed with whole blood incubates as shown in Fig. 3 . In order to identify the enzyme in RBC responsible for the phosphorylation, the identification of the source of phosphoryl transfer could be helpful. Stable isotope Rat blood also generated the phosphorylated metabolite of AZ2381, albeit at a lower yield than mouse blood (Fig. 6) . The yield of phosphorylation product in the freshly collected rat blood was approximately 1/5 of that in freshly collected mouse blood under the same incubation conditions, based on LC-UV peak areas and UV signal response of the phosphorylated metabolite and the parent drug. The phosphorylation was also tested in commercially available Wistar Hanover rat, Beagle dog, and human blood that were delivered to our laboratory overnight inside a cold pack. The phosphorylated metabolite turnover in dog and human blood was even lower than that in rat blood. However, the data are not presented here since the yield in overnight delivered rat blood was substantially lower than that in freshly collected rat blood at our laboratory, thus, the same would be assumed for the dog and human blood. The low level phosphorylation in overnight-delivered rat, dog and human blood was only detectable by LC-MS, but were too low to be seen in LC-UV chromatograms.
DISCUSSION
The fortuitous discovery of the phosphorylation of AZ2381 started with bioanalytical troubleshooting. After the surprising detection of phosphorylated-AZ2381 in mouse plasms samples collected from the AZ2381 dosed animals, the possibility of analytical crosstalk from a common sulfation metabolite was considered. Nevertheless, the temporal profile and dose response of phosphorylated-AZ2381 in mouse plasma after an oral dose of AZ2381 (Fig. 2) the very short LC gradient used in bioanalysis, resulting in crosstalk. However, the sulfate would be readily differentiated from the phosphate by a high-resolution mass spectrometer, because their exact mass would differ by 9.5 mDa (relative error of 18 ppm, Supplemental Fig 3) . We were anticipating to prove this hypothesis of crosstalk, but instead confirmed that it was a rare xenobiotic phosphorylation metabolite (Supplemental Fig. 1 ). As suggested by Mitchell in a recent review article, the possibly misidentification of rare phosphate conjugates of xenobiotics as sulfate conjugates could have happened before the advent of modern LC-MS (Mitchell, 2016) , such as the routine use of high resolution MS in drug metabolism.
Heparin was used as the anticoagulant in this study to prevent chelation of the Mg 2+ which would occur with another commonly used anticoagulant EDTA. The divalent metal ion Mg 2+ is usually required in the kinase-mediated transfer of a phosphoryl group from an organic phosphate source to a kinase substrate (Harding et al., 2010; Matte et al., 1998) . However, the addition of 10 mM MgCl 2 to whole blood and RBC incubations did not enhance phosphorylation in our case ( Fig. 3 and 4 type of divalent metal ion was involved in the phosphorylation. Nevertheless, the inhibitory effect of the metal chelator EDTA on phosphorylation (Fig. 3, 4 and 6) suggests that divalent metal ions are necessary for the phosphorylation reaction
It is known in the literature that some enzymes in leukocytes can metabolize drug molecules, e.g., neutrophil myeloperoxidase (Khan et al., 2016 , Uetrecht, 1994 . The phosphorylation of the immunomodulatory drug fingolimod is catalyzed by sphingosine kinases (Billich et al., 2003) that are present in eukaryotic cells. The phosphorylation of AZ2381 occurred in both immune competent CD-1 mouse and immune deficient SCID and Nude mice, thus T and B lymphocytes that are absent from SCID and Nude mice are not responsible for the phosphorylation. Still, it was a bit surprising that remaining total leukocytes after the lysing of RBCs in the mouse blood gave virtually no phosphorylation of AZ2381 (Fig 3E) , as we were initially misled by a preliminary experiment with an isolated leukocyte fraction that was contaminated by some red blood cells (i.e., a low turnover of phosphorylated-AZ2381 in the contaminated leukocytes fraction, data not shown). The incubations with collected intact RBCs further demonstrated that the phosphorylated metabolite was produced by mouse RBCs (Fig. 4) . Isolation of leukocytes free of RBC contamination was also performed without lysing the red blood cells (Materials and Methods) to further verify that leukocytes were not responsible for the phosphorylation of AZ2381 (Fig. 4) .
The intrinsic rate of the phosphorylation is probably higher than observed in the blood, because the reverse reaction of enzymatic hydrolysis of the organophosphate can occur. The yield of phosphorylation in total cellular fraction after the removal of plasma from mouse blood was 2.6 times that in whole blood (Fig. 4) . This increase in the yield of the phosphorylated metabolite could be rationalized by the removal of alkaline phosphatases and A-esterases present in plasma (Rooseboom et al., 2004 , Rosalki, 1994 Parkinson et al., 2013) . Both alkaline phosphatases and A-esterases would hydrolyze the organophosphate of the metabolite back to parent drug AZ2381. In the stability test of 2 µM phosphorylated-AZ2381 (t 1/2 ) of approximately 4.5 h was observed for the disappearance of phosphorylated-AZ2381 standard, and concurrently AZ2381 was produced from phosphorylated-AZ2381 (Supplemental Fig. 4 ).
The addition of ATP to the in vitro incubation with mouse blood or mouse RBCs did not increase the production of phosphorylated-AZ2381 (Fig. 3 and 4) . This could be explained in two different wayseither a sufficient amount of ATP is originally present in the blood and RBCs, or ATP is not the source of phosphoryl transfer in the RBC-mediated phosphorylation of AZ2381. It is known that ATP is the source of the phosphoryl group in most phosphorylation reactions (Cheek et al., 2002; Matte et al., 1998) .
However, other sources of phosphoryl groups may be used in some phosphorylations. In glycolysis (the sole source of metabolic energy in red blood cells), two inorganic phosphates (not ATP) are utilized to form two 1,3-bisphosphoglycerates which are subsequently used by phosphoglycerate kinase to produce two ATP from two ADP in the payoff phase (Nelson and Cox, 2013 (Hackney, 1984) . On the contrary, chemical exchange of oxygen isotope between dissolved phosphate and water would be extremely slow (Lecuyer et al., 1999) However, a number of questions are still yet to be addressed -whether the low turnover of phosphorylated-AZ2381 in rat blood than in mouse blood was due to the lower formation rate or due to the higher hydrolysis rate of phosphorylated-AZ2381, what specific enzyme in red blood cells is responsible for the phosphorylation, and what structural feature of AZ2381 has triggered a phosphorylation that is usually intended for endogenous substances.
